275 results on '"Verbeke, Geert"'
Search Results
2. COVID-19
3. Missing Data
4. Generalized Estimating Equations
5. Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls
6. An information‐theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: Application to vaccine evaluation
7. Evaluation of a flexible piecewise linear mixed‐effects model in the analysis of randomized cross‐over trials
8. A combined overdispersed longitudinal model for nominal data
9. A joint normal-binary (probit) model for high-dimensional longitudinal data
10. An observational cohort study of histological screening for BK polyomavirus nephropathy following viral replication in plasma
11. A longitudinal transition imputation model for categorical data applied to a large registry dataset
12. Do health beliefs about COVID‐19 predict morbidity? A longitudinal study
13. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK
14. Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
15. A multivariate spatio-temporal model for the incidence of imported COVID-19 cases and COVID-19 deaths in Cuba
16. A longitudinal perspective on perceived vulnerability to disease during the COVID-19 pandemic in Belgium
17. Mixed Models with Emphasis on Large Data Sets
18. Combining Factors from Different Factor Analyses Based on Factor Congruence
19. Do optimism and moralization predict vaccination? A five-wave longitudinal study.
20. Self-uniqueness beliefs and adherence to recommended precautions. A 5-wave longitudinal COVID-19 study
21. A joint normal‐binary (probit) model
22. Modulation of thromboinflammation in hospitalized COVID‐19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn‐Antico study
23. Bias by censoring for competing events in survival analysis
24. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
25. High Security Settings in Flanders: An Analysis of Discharged and Long-Term Forensic Psychiatric Patients
26. Role for Granulocyte Colony‐Stimulating Factor in Neutrophilic Extramedullary Myelopoiesis in a Murine Model of Systemic Juvenile Idiopathic Arthritis
27. Longitudinal Joint Modelling of Binary and Continuous Outcomes: A Comparison of Bridge and Normal Distributions
28. Estimating COVID-19-Related Excess Mortality Excluding Seasonal Phenomena in Belgium
29. Implementing the meta-analytic approach for the evaluation of surrogate endpoints in SAS and R: a word of caution
30. A linear mixed model to estimate COVID‐19‐induced excess mortality
31. Bayesian Model Selection for Longitudinal Count Data
32. A joint transition model for evaluating eGFR as biomarker for rejection after kidney transplantation
33. Repeated Measurements
34. Missing Data
35. Bayesian model selection for multilevel mediation models
36. The evolution of histological changes suggestive of antibody‐mediated injury, in the presence and absence of donor‐specific anti‐HLA antibodies
37. Improved longitudinal data analysis for cross-over design settings, with a piecewise linear mixed-effects model
38. Corrigendum to “itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens”
39. A linear Mixed Model to Estimate COVID-19-induced Excess Mortality
40. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial
41. Longitudinal Joint Modelling of Ordinal and Overdispersed Count Outcomes: A Bridge Distribution for the Ordinal Random Intercept
42. mifa: Multiple Imputation for Exploratory Factor Analysis
43. Direct Antivirals Working against the Novel coronavirus – Azithromycin (DAWn-AZITHRO)A randomized, multicenter, open-label, adaptive, proof of concept clinical trial of new antivirals working against Sars-CoV2 – Azithromycin trial
44. Random Effects Models for Longitudinal Data
45. Parametric modeling of longitudinal data
46. Joint models for longitudinal data
47. Joint models for high-dimensional longitudinal data
48. Sensitivity analysis for incomplete data
49. Kun je met statistiek werkelijk alles bewijzen?
50. A randomized, multicenter, open-label, adaptive, proof of concept clinical trial of new antivirals working against Sars-CoV2: Direct Antivirals Working against the Novel coronavirus – Azithromycin (DAWn-AZITHRO) trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.